This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Veterinary CCL17 Therapeutic Antibody Development
Background of CCL17
In seeking new therapeutic strategies for companion animal cancers, allergic, and autoimmune diseases, the upregulated expression of CCL17 becomes a significant therapeutic target. BioVenic offers a comprehensive one-stop service for veterinary CCL17 therapeutic antibody development. Through our full-process coverage, we support the development of therapeutic antibodies targeting CCL17, exploring their potential to specifically block the interaction between CCL17 and CCR4.
Background of CCL17
| Full Name | C-C motif chemokine ligand 17, thymus and activation-regulated chemokine. |
|---|---|
| Aliases | A-152E5.3, ABCD-2, SCYA17, TARC. |
| Target Profile | As a low molecular weight cytokine in the CC chemokine family, CCL17 is predominantly produced in the thymus by activated antigen-presenting cells such as dendritic cells, monocytes, and macrophages. It exerts chemotactic activity on T lymphocytes by binding to its specific receptor, CCR4, playing a crucial role in thymic T cell development and the trafficking and activation of mature T cells. |
MoA of CCL17
The synthesis and secretion of CCL17 depend on the cell type and specific cytokine stimuli. TNF-α and IFN-γ activate JAK2, p38 MAPK, and Raf-1 via their specific receptors, leading to the activation of STAT1 and NFκB, and consequently, the synthesis of CCL17. In myeloid cells, IL-4 and IL-13 promote CCL17 expression by activating STAT6. Additionally, activated STAT6 increases the transcription of IRF4 and JMJD3, influencing the gene expression of CCL17. The complex signaling networks demonstrate the diversity and intricate regulation of CCL17 synthesis, highlighting its significant role in immune regulation and inflammatory responses. By binding to CCR4, CCL17, which is synthesized and secreted, shows an important role in regulating the differentiation, development, and proliferation of T lymphocytes, B lymphocytes, and dendritic cells.
Fig.1 Schematic diagram of molecular mechanisms for synthesizing CCL17.1
Application in Veterinary Therapeutics
Upon activation of its receptor CCR4, CCL17 can trigger the aggregation of inflammatory and immune cells, leading to the release of inflammatory mediators. CCL17's modulation may also influence the tumor microenvironment by attracting regulatory T cells, enabling some cancers to evade immune responses. In canine, serum levels of CCL17 correlate with the severity of atopic dermatitis, showing the connection with autoimmune and allergic diseases. Overall, as an immunomodulatory factor, CCL17 plays a critical role in a variety of diseases in companion animals, making the development of its antibodies a promising avenue for treatment.
Veterinary CCL17 Therapeutic Antibody Development Services
Aberrant expression of CCL17 is closely linked to various immune-related diseases and cancer types in companion animals. Considering its potential role in treating these diseases, BioVenic focuses on providing comprehensive services for the development of veterinary CCL17 therapeutic antibodies. We utilize different technologies such as hybridoma, single B cell sorting, and phage display to prepare veterinary therapeutic antibodies and complement these with subsequent characterization and engineering services, aiding in developing high-quality veterinary CCL17 therapeutic antibodies. Additionally, we have established a species-specific antibody development platform, relying on a variety of emerging technologies to facilitate targeted antibody development for specific species.
Please click the link below for more information about our veterinary CCL17 therapeutic antibody development services.
Why Choose Us?
BioVenic offers complete veterinary therapeutic antibody development services, including gene synthesis, animal immunization, antibody production, purification, characterization, and so on.
We understand the unique therapeutic needs of different animal species and provide tailored species-specific antibody development solutions to ensure treatment effectiveness and safety.
We adhere to strict quality control standards to ensure the purity and stability of antibody samples throughout the antibody development process.
Given the key role of CCL17 in immune-related diseases and cancers in companion animals, BioVenic's veterinary CCL17 therapeutic antibody development service aims to assist you in exploring a broader range of therapeutic possibilities. If you are interested in learning more about our one-stop veterinary CCL17 therapeutic antibody development services, please do not hesitate to contact us.
References
- Catherine, Julien, and Florence Roufosse. "What does elevated TARC/CCL17 expression tell us about eosinophilic disorders?." Seminars in Immunopathology. Vol. 43. No. 3. Berlin/Heidelberg: Springer Berlin Heidelberg, 2021.
- Asahina, Ryota, et al. "Serum canine thymus and activation‐regulated chemokine (TARC/CCL17) concentrations correlate with disease severity and therapeutic responses in dogs with atopic dermatitis." Veterinary Dermatology 31.6 (2020): 446-455.